KR20240017001A - 가용형 clec2를 이용한 출혈성 뇌졸중의 리스크 평가법 - Google Patents

가용형 clec2를 이용한 출혈성 뇌졸중의 리스크 평가법 Download PDF

Info

Publication number
KR20240017001A
KR20240017001A KR1020237044828A KR20237044828A KR20240017001A KR 20240017001 A KR20240017001 A KR 20240017001A KR 1020237044828 A KR1020237044828 A KR 1020237044828A KR 20237044828 A KR20237044828 A KR 20237044828A KR 20240017001 A KR20240017001 A KR 20240017001A
Authority
KR
South Korea
Prior art keywords
hemorrhagic stroke
concentration
patient
sclec2
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237044828A
Other languages
English (en)
Korean (ko)
Inventor
히데오 와다
마사히데 카와무라
Original Assignee
피에이치씨 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피에이치씨 주식회사 filed Critical 피에이치씨 주식회사
Publication of KR20240017001A publication Critical patent/KR20240017001A/ko
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020237044828A 2021-05-31 2022-05-31 가용형 clec2를 이용한 출혈성 뇌졸중의 리스크 평가법 Pending KR20240017001A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2021-091607 2021-05-31
JP2021091607 2021-05-31
PCT/JP2022/022077 WO2022255349A1 (ja) 2021-05-31 2022-05-31 可溶型ｃｌｅｃ２を用いた出血性脳卒中のリスク評価法

Publications (1)

Publication Number Publication Date
KR20240017001A true KR20240017001A (ko) 2024-02-06

Family

ID=84323410

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237044828A Pending KR20240017001A (ko) 2021-05-31 2022-05-31 가용형 clec2를 이용한 출혈성 뇌졸중의 리스크 평가법

Country Status (6)

Country Link
US (1) US20240264175A1 (https=)
EP (1) EP4350350A4 (https=)
JP (1) JPWO2022255349A1 (https=)
KR (1) KR20240017001A (https=)
CN (1) CN117769652A (https=)
WO (1) WO2022255349A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025075139A1 (ja) * 2023-10-06 2025-04-10 Ｐｈｃ株式会社 可溶型ｃｌｅｃ－２を用いた脳心血管・腎イベントの長期的発症ハイリスク評価法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6078845U (ja) 1983-11-04 1985-06-01 ライオン株式会社 食用廃油固化処理用具
JP2020032797A (ja) 2018-08-28 2020-03-05 スズキ株式会社 ニーエアバッグ取付け構造
JP2021003671A (ja) 2019-06-26 2021-01-14 稔 甲斐 閉塞防止機能付振動篩用網及び振動篩装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002359815A1 (en) * 2001-12-19 2003-07-09 Immunex Corporation C-type lectin polypeptide, polynucleotide and methods of making and use thereof
JP6078845B2 (ja) * 2012-09-28 2017-02-15 株式会社Ｌｓｉメディエンス 可溶型ｃｌｅｃ−２に基づく血小板活性化測定方法
US10227407B2 (en) * 2013-10-10 2019-03-12 Yukinari Kato Anti-podoplanin antibody
EP4113524A4 (en) * 2020-02-28 2024-03-06 LSI Medience Corporation METHOD FOR MEASURING PLATELE ACTIVATION BASED ON SOLUBLE CLEC-2 AND PLATELE COUNT

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6078845U (ja) 1983-11-04 1985-06-01 ライオン株式会社 食用廃油固化処理用具
JP2020032797A (ja) 2018-08-28 2020-03-05 スズキ株式会社 ニーエアバッグ取付け構造
JP2021003671A (ja) 2019-06-26 2021-01-14 稔 甲斐 閉塞防止機能付振動篩用網及び振動篩装置

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
F. Kazama et al., Platelets 2015; 26(8):711-719
Y. Yamashita et al., Thrombosis Research 178(2019) 54-58

Also Published As

Publication number Publication date
JPWO2022255349A1 (https=) 2022-12-08
WO2022255349A1 (ja) 2022-12-08
EP4350350A1 (en) 2024-04-10
US20240264175A1 (en) 2024-08-08
CN117769652A (zh) 2024-03-26
EP4350350A4 (en) 2025-04-30

Similar Documents

Publication Publication Date Title
JP7546037B2 (ja) 可溶型ｃｌｅｃ－２と血小板数に基づく血小板活性化測定方法
Qi et al. The predictive and diagnostic ability of IL-6 for postoperative urosepsis in patients undergoing percutaneous nephrolithotomy
Ando et al. Elevated ratio of C-type lectin-like receptor 2 level and platelet count (C2PAC) aids in the diagnosis of post-operative venous thromboembolism in IDH-wildtype gliomas
JP2009539080A (ja) 急性冠状動脈症候群のリスクを有する個体の識別のためのｍｒｐ８／１４レベルの使用
CN106257287B (zh) 生长分化因子15评估高血压患者首发脑卒中的新应用
KR20240017001A (ko) 가용형 clec2를 이용한 출혈성 뇌졸중의 리스크 평가법
Halil et al. Serum endocan level as a predictive marker for hemodynamically significant patent ductus arteriosus in very low birth weight infants
Kong et al. Plasma level of D-dimer is an independent diagnostic biomarker for deep venous thrombosis in patients with ischemic stroke
EP4350349A1 (en) Method for evaluating risk of acute cerebral vascular disease using soluble clec2
HK40106384A (en) Method for assessing risk of hemorrhagic stroke using soluble clec2
US20200147125A1 (en) Detection of high risk arterial thromboembolic diseases by markers of coagulation and hemostatic activation
JPWO2022255348A5 (https=)
HK40105374A (en) Method for evaluating risk of acute cerebral vascular disease using soluble clec2
HK40127498A (en) Method for evaluating risk of acute cerebral vascular disease using soluble clec2
JP2023519654A (ja) 脳卒中の評価のためのｒｅｔ（トランスフェクション再編成）
JP7808059B2 (ja) 可溶型ｃｌｅｃ２を用いた癌患者における血栓症リスクの予測方法
RU2851668C1 (ru) Способ прогнозирования риска развития спонтанных гематом у больных COVID-19
Saadeldin et al. Soluble p-selectin level in patients with deep venous thrombosis
WO2025075139A1 (ja) 可溶型ｃｌｅｃ－２を用いた脳心血管・腎イベントの長期的発症ハイリスク評価法
HK40085757A (en) Method for measuring platelet activation based on soluble clec-2 and platelet count
Dong et al. Prognostic Value of Admission Blood Urea Nitrogen/Creatinine Ratio in Patients with STEMI Undergoing Late Percutaneous Coronary Intervention
RU2602914C1 (ru) Способ оценки степени тяжести воспалительных заболеваний органов малого таза
Abdullah et al. Diagnostic Value of D-Dimer’s Serum Level in Patients with Cerebral Venous Thrombosis
Hsiao et al. D-dimer assay not adequate for spontaneous intracranial hemorrhage screening
KOCYIGIT et al. Raftlin, presepsin levels and thiol-disulphide homeostasis in acute appendicitis: A pilot study.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231226

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250307

Comment text: Request for Examination of Application